XIAP and liver cancer: Altogether, the results demonstrated that the XIAP inhibitor AZD5582 in combination with IMWA drastically inhibited the progression of liver cancer tissue in immunity-intact mice, and the XIAP inhibitor also inhibited the progression of liver cancer tissue in immunity-deficient mice.